Pharmacotherapy of resistant arterial hypertension
- 作者: Shepeleva N1, Rodionov A1, Fomin V1
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- 期: 卷 90, 编号 4 (2018)
- 页面: 4-7
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32437
- ID: 32437
如何引用文章
全文:
详细
作者简介
N Shepeleva
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)врач-терапевт лечебно-диагностического отделения Университетской клинической больницы №1 Moscow, Russia
A Rodionov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)врач-кардиолог лечебно-диагностического отделения Университетской клинической больницы №1 Moscow, Russia
V Fomin
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: fomin_vic@mail.ru
член-корр. РАН, проректор по научно-исследовательской и лечебной работе, д.м.н., проф. каф. внутренних, профессиональных болезней и пульмонологии медико-профилактического факультета Moscow, Russia
参考
- Lim S.S, Vos T, Flaxman A.D, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2224-60. doi: 10.1016/S0140-6736(12)61766-8
- Daugherty S.L, Powers J.D, Magid D.J, Tavel H.M, Masoudi F.A, Margolis K.L, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42. doi: 10.1161/ CIRCULATIONAHA.111.068064
- Smith S.M, Gong Y, Handberg E, Messerli F.H, Bakris G.L, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635-43. doi: 10.1097/HJH.0000000000000051
- Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80. doi: 10.1161/HYPERTENSIONAHA.111.170308
- De la Sierra A, Segura J, Banegas J.R, Gorostidi M, Juan J, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classifi ed on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902. doi: 10.1161/HYPERTENSIONAHA.110.168948
- Sim J.J, Bhandari S.K, Shi J, Liu ILA, Calhoun D.A, Mc Glynn E.A, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Elsevier; 2013. P. 1099-107.
- Achelrod D, Wenzel U, Frey S. Systematic review and meta - analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355-61. doi: 10.1093/ajh/ hpu151
- Garg J.P, Elliott W.J, Folker A, Izhar M, Black H.R. RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university - based cohorts. Am J Hypertens. 2005;18(5, Pt. 1):619-26. doi: 10.1016/j.amjhyper.2004.11.021
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. doi: 10.1093/eurheartj/eht151
- Krause T, Lovibond K, Caulfield M, Mc Cormack T, Williams B. Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;25:343:d4891.
- Whelton P.K, Carey R.M, Aronow W.S, Casey D.E. Jr, Collins K.J, Dennison Himmelfarb C, De Palma S.M, Gidding S, Jamerson K.A, Jones D.W, Mac Laughlin E.J, Muntner P, Ovbiagele B, Smith S.C. Jr, Spencer C.C, Stafford R.S, Taler S.J, Thomas R.J, Williams K.A. Sr, Williamson J.D, Wright J.T. Jr. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 Nov 13.
- Moser M, Setaro J.F. Clinical practice. Resistant or difficult - to - control hypertension. N Engl J Med. 2006 Jul 27;355(4):385-92. doi: 10.1056/NEJMcp041698
- Chazova I, Schlaich M.P. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Intern J Hypertens. 2013;2013:541689. doi: 10.1155/2013/541689
- Taler S, Textor S, Augustine J. Resistant hypertension. Comparing hemodynamic management to specialist care. Hypertension. 2002;39:982-8. doi: 10.1161/01.HYP.0000016176.16042.2F
- Hirsch S. A different approach to resistant hypertension. Cleve Clin J Med. 2007 Jun;74(6):449-56. doi: 10.3949/ccjm.74.6.449
- Graves J, Bloomfield R, Buckalew V. Plasma volume in resistant hypertension: Guide to pathophysiology and therapy. Am J Med Sci. 1989;298:361-5. doi: 10.1097/00000441-198912000-00001
- Ramsey L, Silas J, Freestone S. Diuretic treatment of resistant hypertension. BMJ. 1980;281:1101-3. doi: 10.1136/bmj.281.6248.1101
- Mann S.J. Drug therapy for resistant hypertension: a simplified, mechanistic approach. J Clin Hypertens (Greenwich). 2011;13:120-30. doi: 10.1111/j.1751-7176.2010.00387.x
- Mann S.J, Parikh N.S. A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. J Clin Hypertens (Greenwich). 2012;14:191-7. doi: 10.1111/j.1751-7176.2012. 00605.x
- Egan B.M, Basile J.N, Rehman S.U, et al. Plasma Renin Test - Guided Drug Treatment Algorithm for Correcting Patients With Treated but Uncontrolled Hypertension: A Randomized Controlled Trial. J Hypertens. 2009 Jul 1;22(7):792-801. doi: 10.1038/ajh.2009.63
- Furberg C.D. Renin Test-Guided Drug Treatment of Hypertension: The Need For Clinical Trials. Am J Hypertens. 2011;24(11):1158-63. doi: 10.1038/ajh.2011.170
- Garg J.P, Elliott W.J, Folker A, Izhar M, Black H.R. Resistant hypertension revisited: a comparison of two university - based cohorts. Am J Hypertens. 2005;18:619-26. doi: 10.1016/j.amjhyper.2004.11.021
- Calhoun D. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006;1:1039-45. doi: 10.2215/CJN.01060306
- Minutolo R, De Nicola L, Zamboli P, et al. Management of hypertension in patients with CKD: Differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46:18-25. doi: 10.1053/ j.ajkd.2005.03.019
- De Nicola L, Minutolo R, Chiodini P, et al. Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int. 2006;69:538-45. doi: 10.1038/sj.ki.5000085
- The African American Study of Kidney Disease and Hypertension Group (AASK). Successful blood pressure control in the African American study of kidney disease and hypertension. Arch Intern Med. 2002;162:1636-43. doi: 10.1001/archinte.162.14.1636
- Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9. doi: 10.1056/NEJMoa011161
- Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin - angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012 Aug;30(8):1656-64. doi: 10.1097/HJH.0b013e 3283551e98
- Václavík J, Sedlák R, Jarkovský J, Kociánová E, Táborský M. Effect of spironolactone in resistant arterial hypertension: a randomized, double - blind, placebo - controlled trial (ASPIRANT-EXT). Medicine (Baltimore). 2014 Dec;93(27):e162. doi: 10.1097/MD.0000000000000162
- Williams B, Mac Donald T.M, Caulfield M, Cruickshank J.K, Mc Innes G, Sever P, Webb D.J, Salsbury J, Morant S, Ford I, Brown M.J. Prevention And Treatment of Hypertension With Algorithm - based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug - resistant hypertension. BMJ Open. 2015 Aug 7;5(8):e008951. doi: 10.1136/bmjopen-2015-008951
- Williams B, Mac Donald T.M, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug - resistant hypertension (PATHWAY-2): a randomised, double - blind, crossover trial. Lancet. 2015;386(10008):2059-68. doi: 10.1016/ S0140-6736(15)00257-3